Nuformix further evaluating NXP002 combination therapies now underway

Nuformix plc

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment for Idiopathic Pulmonary Fibrosis.

As previously announced, the Company has initiated studies in 3D human IPF lung tissue using a disease and species relevant model, and is working with its partner, Fibrofind, focusing on NXP002 in combination with current standards of care.  Suitable human disease tissue, which is highly limited in supply, has now been acquired allowing the practical elements of the study to commence, with results and further updates to be announced in due course.

NXP002 combinations have already shown promise in human diseased IPF tissue, showing a pleasing synergistic efficacy effect with low doses of standards-of-care, resulting in the Group filing a new combination patent application in 2022.

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: We’ve had to wait a little longer than expected to acquire suitable tissue, but I’m delighted that the main element of this key study, further evaluating NXP002 combination therapies is now underway and I look forward to sharing the results when they are available.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF.

Nuformix to present NXP002 data at ATS 2025

Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges.

Nuformix advances NXP002 as EMA backs Orphan Drug status

Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights.

Nuformix secures positive EMA opinion for orphan drug status in IPF

Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF).

Nuformix updates Registered Office and Company Secretary

Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary.

Nuformix reports positive NXP002 results in lung disease models

Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways.

Search

Search